{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=XLA&page=2", "query": { "condition": "XLA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=XLA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T14:01:37.191Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06588478", "title": "A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2025-01-03", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 21, "location_summary": "Chandler, Arizona • Duarte, California • Irvine, California + 17 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06588478" }, { "nct_id": "NCT02784106", "title": "Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "M2951", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 65, "start_date": "2016-07-31", "completion_date": "2017-11-14", "has_results": true, "last_update_posted_date": "2018-07-17", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 1, "location_summary": "Billerica, Massachusetts", "locations": [ { "city": "Billerica", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02784106" }, { "nct_id": "NCT06799000", "title": "A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Remibrutinib Dose A", "type": "DRUG" }, { "name": "Remibrutinib Dose B", "type": "DRUG" }, { "name": "Placebo 1", "type": "DRUG" }, { "name": "Placebo 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 588, "start_date": "2025-01-31", "completion_date": "2027-10-04", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799000" }, { "nct_id": "NCT00001244", "title": "Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "XLA", "CVID", "Yao Syndrome", "Blau Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "2 Years to 120 Years" }, "enrollment_count": 500, "start_date": "1990-01-15", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001244" }, { "nct_id": "NCT03233230", "title": "Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "M2591 25 mg QD", "type": "DRUG" }, { "name": "M2951 75 mg QD", "type": "DRUG" }, { "name": "M2951 50 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 390, "start_date": "2017-09-18", "completion_date": "2019-09-23", "has_results": true, "last_update_posted_date": "2020-09-28", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 8, "location_summary": "Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Leandro", "state": "California" }, { "city": "DeBary", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03233230" }, { "nct_id": "NCT01841723", "title": "Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hairy Cell Leukemia", "Hairy Cell Leukemia Variant", "Recurrent Hairy Cell Leukemia", "Recurrent Hairy Cell Leukemia Variant" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2013-04-30", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 5, "location_summary": "Bethesda, Maryland • Detroit, Michigan • Rochester, Minnesota + 2 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01841723" }, { "nct_id": "NCT05990465", "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "LV20.19 CAR T cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "81 Years", "sex": "ALL", "summary": "18 Years to 81 Years" }, "enrollment_count": 12, "start_date": "2025-02-06", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05990465" }, { "nct_id": "NCT01980628", "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma", "B-cell Lymphoma" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2013-12", "completion_date": "2017-10-02", "has_results": true, "last_update_posted_date": "2019-10-16", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 13, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980628" }, { "nct_id": "NCT01578707", "title": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ofatumumab", "type": "DRUG" }, { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 391, "start_date": "2012-06", "completion_date": "2018-10-25", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 25, "location_summary": "La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578707" }, { "nct_id": "NCT06846671", "title": "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CLL", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "BGB-16673", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2025-04-10", "completion_date": "2030-02-14", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T14:01:37.191Z", "location_count": 21, "location_summary": "Jonesboro, Arkansas • Los Angeles, California • Whittier, California + 17 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846671" } ] }